about
Bioresorbable scaffolds: a new paradigm in percutaneous coronary interventionCoronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.Assessment of the hemodynamic characteristics of Absorb BVS in a porcine coronary artery model.A Novel Algorithm to Quantify Coronary Remodeling Using Inferred Normal Dimensions.Coronary stent thrombosis: what have we learned?Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery.From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease.Validation of coronary computed tomography angiography scores for non-invasive assessment of atherosclerotic burden through a comparison with multivessel intravascular ultrasound.Single or dual antiplatelet therapy after PCI.Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview.Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease.Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease: An External Validation of the SYNTAX Score II Model in the 1,480 Patients of the BEST aLong-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel Disease.Coronary Artery Bypass Grafting Versus Drug-Eluting Stents Implantation for Previous Myocardial Infarction.Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography.Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.Spontaneous closure of post-intervention left anterior descending coronary pseudoaneurysm.A simplified and reproducible method to size the mitral annulus: implications for transcatheter mitral valve replacement.Pressure-mediated versus pharmacologic treatment of radial artery spasm during cardiac catheterisation: a randomised pilot study.Non-invasive Heart Team assessment of multivessel coronary disease with coronary computed tomography angiography based on SYNTAX score II treatment recommendations: design and rationale of the randomised SYNTAX III Revolution trial.Angiographic assessment of aortic regurgitation by video-densitometry in the setting of TAVI: Echocardiographic and clinical correlates.Misogyny in heart disease?Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?Periprocedural myocardial infarction in stent trials: how universal is the third universal definition?Edge Vascular Response After Resorption of the Everolimus-Eluting Bioresorbable Vascular Scaffold - A 5-Year Serial Optical Coherence Tomography Study.Progression of calcification after implantation of a fully bioresorbable scaffold: A serial and combined IVUS-OCT follow-up of 5years.Quantification by optical coherence tomography imaging of the ablation volume obtained with the Orbital Atherectomy System in calcified coronary lesions.Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study.The interaction of de novo and pre-existing aortic regurgitation after TAVI: insights from a new quantitative aortographic technique.Circulatory support in cardiogenic shock after acute myocardial infarctionTools and Techniques - Clinical: SYNTAX score II calculatorReply: Long-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel DiseaseReply: Percutaneous Revascularization of Left Main Disease: Could the Angiographic Follow-Up Improve the Survival?
P50
Q26766579-D1E468C4-0B75-45AC-9E95-8A9805FC2ECCQ31150789-E44E92E8-96E1-451B-AD8B-4779501A2CEDQ36191090-E1B2CA64-5498-4957-9CF6-433AB89150F2Q36248163-283FAD6C-88F5-49C9-BB30-D544E1C1E006Q37121422-0574D769-94A4-4EF2-BBFC-54784737D51FQ38387360-95DE2D76-31E7-4265-BFC4-BD1295655A5CQ38702003-5B5E6D24-D6A0-491D-BA69-D057CA11466EQ38854543-6035D794-9898-434D-B3CC-D64B744011EAQ38910965-3B4F27BC-FA18-4C31-B1DE-9FF14B91F8DEQ38970275-4FA0FB29-E3FA-4B04-8D9C-66587590F1B2Q39097251-6E377343-F12A-4C0F-9CC1-403E56BFCACEQ39431666-672D1BE8-1941-42BC-9BDB-3C2300D6CD74Q39524120-7FDFA0F5-33A5-404D-9E0C-2BFF87D61932Q39641675-36F02E9F-F408-4B95-BC57-B04D9B9C8B90Q40753201-BB638767-849F-470D-8842-D8C7664FDDA4Q42000738-002DA485-FA97-4EF1-BFB2-0E691E779D83Q42091990-1CF08B88-9273-40E4-9FF5-982E8BF1E7E1Q45153225-1AEECFAA-352C-4AD1-A7EA-B2E163E626C0Q47293172-34B69FEE-EBCD-4C56-8EEF-943AB267BE3BQ48902294-4B2C3A86-D9B3-4A97-A395-F37E29FFEA6AQ48902318-1A7D7F43-8820-48F0-B292-2A1861ADEB80Q50941747-B0307C7A-902E-4DA0-AC4E-9D69A81519A1Q50997619-46996017-F158-4062-8AE8-591E7BE0CF11Q51141670-4D49A446-C8EA-4AB1-82BF-ED88DE016698Q51160975-D660A9EC-0EDB-4FB8-9E98-BF5F413BEFCAQ51473794-0876F9DB-3355-4D87-9316-D8FB0A675465Q51508694-111C2E5D-4DF9-4EF3-81FE-23E6B9B64FA1Q52878420-177E78B0-D5D0-4E30-B4A9-CE6E9CCDACE5Q53267036-F338C4AD-9BC7-416B-B875-38D8198395E3Q53622912-A7E8D459-D126-4B81-8BA7-41086741AE2CQ84795119-2DE0113D-6E07-454B-92DA-36284CA802B1Q89425342-30D4890A-DA3A-484F-932B-5F00B3BA7079Q89455384-5B68B163-F396-4B30-9E85-9438EE95EB9AQ89932514-E5ECFA45-29DC-4567-AD3E-CC433878B89F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rafael Cavalcante
@ast
Rafael Cavalcante
@en
Rafael Cavalcante
@es
Rafael Cavalcante
@nl
Rafael Cavalcante
@sl
type
label
Rafael Cavalcante
@ast
Rafael Cavalcante
@en
Rafael Cavalcante
@es
Rafael Cavalcante
@nl
Rafael Cavalcante
@sl
altLabel
Rafael Cavalcante e Silva
@en
prefLabel
Rafael Cavalcante
@ast
Rafael Cavalcante
@en
Rafael Cavalcante
@es
Rafael Cavalcante
@nl
Rafael Cavalcante
@sl
P1053
H-9553-2013
P106
P21
P31
P3829
P496
0000-0003-0158-811X